HRP20191074T1 - Polimeri koji vežu protone za oralnu primjenu - Google Patents
Polimeri koji vežu protone za oralnu primjenu Download PDFInfo
- Publication number
- HRP20191074T1 HRP20191074T1 HRP20191074TT HRP20191074T HRP20191074T1 HR P20191074 T1 HRP20191074 T1 HR P20191074T1 HR P20191074T T HRP20191074T T HR P20191074TT HR P20191074 T HRP20191074 T HR P20191074T HR P20191074 T1 HRP20191074 T1 HR P20191074T1
- Authority
- HR
- Croatia
- Prior art keywords
- cross
- amine
- bis
- linked
- pharmaceutical composition
- Prior art date
Links
- 229920000642 polymer Polymers 0.000 title claims 17
- 150000001412 amines Chemical class 0.000 claims 32
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 12
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 239000000825 pharmaceutical preparation Substances 0.000 claims 11
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 238000006116 polymerization reaction Methods 0.000 claims 6
- 239000011780 sodium chloride Substances 0.000 claims 6
- 239000000872 buffer Substances 0.000 claims 5
- 239000003431 cross linking reagent Substances 0.000 claims 5
- 239000000178 monomer Substances 0.000 claims 5
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 claims 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 4
- 239000012530 fluid Substances 0.000 claims 4
- 230000002496 gastric effect Effects 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- YHRUOJUYPBUZOS-UHFFFAOYSA-N 1,3-dichloropropane Chemical compound ClCCCCl YHRUOJUYPBUZOS-UHFFFAOYSA-N 0.000 claims 3
- 239000008367 deionised water Substances 0.000 claims 3
- 229910021641 deionized water Inorganic materials 0.000 claims 3
- 230000008961 swelling Effects 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- IBYHHJPAARCAIE-UHFFFAOYSA-N 1-bromo-2-chloroethane Chemical compound ClCCBr IBYHHJPAARCAIE-UHFFFAOYSA-N 0.000 claims 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 2
- VOUJQKYOLXSFCM-UHFFFAOYSA-N 3-chloro-n-(3-chloropropyl)propan-1-amine Chemical compound ClCCCNCCCCl VOUJQKYOLXSFCM-UHFFFAOYSA-N 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- 125000001931 aliphatic group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims 2
- OTBHHUPVCYLGQO-UHFFFAOYSA-N bis(3-aminopropyl)amine Chemical compound NCCCNCCCN OTBHHUPVCYLGQO-UHFFFAOYSA-N 0.000 claims 2
- VHRGRCVQAFMJIZ-UHFFFAOYSA-N cadaverine Chemical compound NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 claims 2
- 238000004132 cross linking Methods 0.000 claims 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 235000019799 monosodium phosphate Nutrition 0.000 claims 2
- GAXGZXPYWABFNX-UHFFFAOYSA-N n,n'-bis(3-chloropropyl)ethane-1,2-diamine Chemical compound ClCCCNCCNCCCCl GAXGZXPYWABFNX-UHFFFAOYSA-N 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 238000010526 radical polymerization reaction Methods 0.000 claims 2
- 210000000813 small intestine Anatomy 0.000 claims 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims 2
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 2
- XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 claims 2
- 229920002554 vinyl polymer Polymers 0.000 claims 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims 1
- OPCJOXGBLDJWRM-UHFFFAOYSA-N 1,2-diamino-2-methylpropane Chemical compound CC(C)(N)CN OPCJOXGBLDJWRM-UHFFFAOYSA-N 0.000 claims 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 claims 1
- UYBWIEGTWASWSR-UHFFFAOYSA-N 1,3-diaminopropan-2-ol Chemical compound NCC(O)CN UYBWIEGTWASWSR-UHFFFAOYSA-N 0.000 claims 1
- VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-dibromopropane Chemical compound BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 claims 1
- RVJABZUDCPZPPM-UHFFFAOYSA-N 1,4,7,10,13,16-hexazacyclooctadecane Chemical compound C1CNCCNCCNCCNCCNCCN1 RVJABZUDCPZPPM-UHFFFAOYSA-N 0.000 claims 1
- QBPPRVHXOZRESW-UHFFFAOYSA-N 1,4,7,10-tetraazacyclododecane Chemical compound C1CNCCNCCNCCN1 QBPPRVHXOZRESW-UHFFFAOYSA-N 0.000 claims 1
- ITWBWJFEJCHKSN-UHFFFAOYSA-N 1,4,7-triazonane Chemical compound C1CNCCNCCN1 ITWBWJFEJCHKSN-UHFFFAOYSA-N 0.000 claims 1
- MDAXKAUIABOHTD-UHFFFAOYSA-N 1,4,8,11-tetraazacyclotetradecane Chemical compound C1CNCCNCCCNCCNC1 MDAXKAUIABOHTD-UHFFFAOYSA-N 0.000 claims 1
- KUFDRRWNPNXBRF-UHFFFAOYSA-N 1,4,8,12-tetrazacyclopentadecane Chemical compound C1CNCCCNCCNCCCNC1 KUFDRRWNPNXBRF-UHFFFAOYSA-N 0.000 claims 1
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 claims 1
- PWGJDPKCLMLPJW-UHFFFAOYSA-N 1,8-diaminooctane Chemical compound NCCCCCCCCN PWGJDPKCLMLPJW-UHFFFAOYSA-N 0.000 claims 1
- VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 claims 1
- DDHUNHGZUHZNKB-UHFFFAOYSA-N 2,2-dimethylpropane-1,3-diamine Chemical compound NCC(C)(C)CN DDHUNHGZUHZNKB-UHFFFAOYSA-N 0.000 claims 1
- UWMHHZFHBCYGCV-UHFFFAOYSA-N 2,3,2-tetramine Chemical compound NCCNCCCNCCN UWMHHZFHBCYGCV-UHFFFAOYSA-N 0.000 claims 1
- GFIWSSUBVYLTRF-UHFFFAOYSA-N 2-[2-(2-hydroxyethylamino)ethylamino]ethanol Chemical compound OCCNCCNCCO GFIWSSUBVYLTRF-UHFFFAOYSA-N 0.000 claims 1
- FDAYLTPAFBGXAB-UHFFFAOYSA-N 2-chloro-n,n-bis(2-chloroethyl)ethanamine Chemical compound ClCCN(CCCl)CCCl FDAYLTPAFBGXAB-UHFFFAOYSA-N 0.000 claims 1
- KDRUIMNNZBMLJR-UHFFFAOYSA-N 2-isopropylaminoethylamine Chemical compound CC(C)NCCN KDRUIMNNZBMLJR-UHFFFAOYSA-N 0.000 claims 1
- JZUHIOJYCPIVLQ-UHFFFAOYSA-N 2-methylpentane-1,5-diamine Chemical compound NCC(C)CCCN JZUHIOJYCPIVLQ-UHFFFAOYSA-N 0.000 claims 1
- JOMNTHCQHJPVAZ-UHFFFAOYSA-N 2-methylpiperazine Chemical compound CC1CNCCN1 JOMNTHCQHJPVAZ-UHFFFAOYSA-N 0.000 claims 1
- BDXGMDGYOIWKIF-UHFFFAOYSA-N 2-methylpropane-1,3-diamine Chemical compound NCC(C)CN BDXGMDGYOIWKIF-UHFFFAOYSA-N 0.000 claims 1
- RXFCIXRFAJRBSG-UHFFFAOYSA-N 3,2,3-tetramine Chemical compound NCCCNCCNCCCN RXFCIXRFAJRBSG-UHFFFAOYSA-N 0.000 claims 1
- KTLIZDDPOZZHCD-UHFFFAOYSA-N 3-(2-aminoethylamino)propan-1-ol Chemical compound NCCNCCCO KTLIZDDPOZZHCD-UHFFFAOYSA-N 0.000 claims 1
- -1 3-(methylamino)pyrrolidino Chemical group 0.000 claims 1
- PQIYSSSTRHVOBW-UHFFFAOYSA-N 3-bromopropan-1-amine;hydron;bromide Chemical compound Br.NCCCBr PQIYSSSTRHVOBW-UHFFFAOYSA-N 0.000 claims 1
- 208000010444 Acidosis Diseases 0.000 claims 1
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 claims 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims 1
- 206010027417 Metabolic acidosis Diseases 0.000 claims 1
- CJKRXEBLWJVYJD-UHFFFAOYSA-N N,N'-diethylethylenediamine Chemical compound CCNCCNCC CJKRXEBLWJVYJD-UHFFFAOYSA-N 0.000 claims 1
- 125000002723 alicyclic group Chemical group 0.000 claims 1
- 125000000746 allylic group Chemical group 0.000 claims 1
- LHIJANUOQQMGNT-UHFFFAOYSA-N aminoethylethanolamine Chemical compound NCCNCCO LHIJANUOQQMGNT-UHFFFAOYSA-N 0.000 claims 1
- IMUDHTPIFIBORV-UHFFFAOYSA-N aminoethylpiperazine Chemical compound NCCN1CCNCC1 IMUDHTPIFIBORV-UHFFFAOYSA-N 0.000 claims 1
- 239000012062 aqueous buffer Substances 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 150000001555 benzenes Chemical class 0.000 claims 1
- 235000010290 biphenyl Nutrition 0.000 claims 1
- 239000004305 biphenyl Substances 0.000 claims 1
- TXFLGZOGNOOEFZ-UHFFFAOYSA-N bis(2-chloroethyl)amine Chemical compound ClCCNCCCl TXFLGZOGNOOEFZ-UHFFFAOYSA-N 0.000 claims 1
- MRNZSTMRDWRNNR-UHFFFAOYSA-N bis(hexamethylene)triamine Chemical compound NCCCCCCNCCCCCCN MRNZSTMRDWRNNR-UHFFFAOYSA-N 0.000 claims 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- YQLZOAVZWJBZSY-UHFFFAOYSA-N decane-1,10-diamine Chemical compound NCCCCCCCCCCN YQLZOAVZWJBZSY-UHFFFAOYSA-N 0.000 claims 1
- 150000004985 diamines Chemical class 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- PWSKHLMYTZNYKO-UHFFFAOYSA-N heptane-1,7-diamine Chemical compound NCCCCCCCN PWSKHLMYTZNYKO-UHFFFAOYSA-N 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 claims 1
- 229920001519 homopolymer Polymers 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- HKAXXLXZPQLQHR-UHFFFAOYSA-N n',2-dimethylpropane-1,3-diamine Chemical compound CNCC(C)CN HKAXXLXZPQLQHR-UHFFFAOYSA-N 0.000 claims 1
- QMXSDTGNCZVWTB-UHFFFAOYSA-N n',n'-bis(3-aminopropyl)propane-1,3-diamine Chemical compound NCCCN(CCCN)CCCN QMXSDTGNCZVWTB-UHFFFAOYSA-N 0.000 claims 1
- HYSQEYLBJYFNMH-UHFFFAOYSA-N n'-(2-aminoethyl)-n'-methylethane-1,2-diamine Chemical compound NCCN(C)CCN HYSQEYLBJYFNMH-UHFFFAOYSA-N 0.000 claims 1
- OTDKXAKMLKPMDA-UHFFFAOYSA-N n'-(3-aminopropyl)-n'-[2-[bis[2-[bis(3-aminopropyl)amino]ethyl]amino]ethyl]propane-1,3-diamine Chemical compound NCCCN(CCCN)CCN(CCN(CCCN)CCCN)CCN(CCCN)CCCN OTDKXAKMLKPMDA-UHFFFAOYSA-N 0.000 claims 1
- KMBPCQSCMCEPMU-UHFFFAOYSA-N n'-(3-aminopropyl)-n'-methylpropane-1,3-diamine Chemical compound NCCCN(C)CCCN KMBPCQSCMCEPMU-UHFFFAOYSA-N 0.000 claims 1
- DFPGBRPWDZFIPP-UHFFFAOYSA-N n'-butylethane-1,2-diamine Chemical compound CCCCNCCN DFPGBRPWDZFIPP-UHFFFAOYSA-N 0.000 claims 1
- SCZVXVGZMZRGRU-UHFFFAOYSA-N n'-ethylethane-1,2-diamine Chemical compound CCNCCN SCZVXVGZMZRGRU-UHFFFAOYSA-N 0.000 claims 1
- KFIGICHILYTCJF-UHFFFAOYSA-N n'-methylethane-1,2-diamine Chemical compound CNCCN KFIGICHILYTCJF-UHFFFAOYSA-N 0.000 claims 1
- QHJABUZHRJTCAR-UHFFFAOYSA-N n'-methylpropane-1,3-diamine Chemical compound CNCCCN QHJABUZHRJTCAR-UHFFFAOYSA-N 0.000 claims 1
- KFDIDIIKNMZLRZ-UHFFFAOYSA-N n'-propan-2-ylpropane-1,3-diamine Chemical compound CC(C)NCCCN KFDIDIIKNMZLRZ-UHFFFAOYSA-N 0.000 claims 1
- MFIGJRRHGZYPDD-UHFFFAOYSA-N n,n'-di(propan-2-yl)ethane-1,2-diamine Chemical compound CC(C)NCCNC(C)C MFIGJRRHGZYPDD-UHFFFAOYSA-N 0.000 claims 1
- KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 claims 1
- KGHYGBGIWLNFAV-UHFFFAOYSA-N n,n'-ditert-butylethane-1,2-diamine Chemical compound CC(C)(C)NCCNC(C)(C)C KGHYGBGIWLNFAV-UHFFFAOYSA-N 0.000 claims 1
- ZKEGVCJAZHCGTG-UHFFFAOYSA-N n,n,n',n'-tetrakis(2-aminoethyl)propane-1,3-diamine Chemical group NCCN(CCN)CCCN(CCN)CCN ZKEGVCJAZHCGTG-UHFFFAOYSA-N 0.000 claims 1
- LYBWJVKFJAIODE-UHFFFAOYSA-N n,n,n',n'-tetrakis(3-aminopropyl)butane-1,4-diamine Chemical compound NCCCN(CCCN)CCCCN(CCCN)CCCN LYBWJVKFJAIODE-UHFFFAOYSA-N 0.000 claims 1
- UQUPIHHYKUEXQD-UHFFFAOYSA-N n,n′-dimethyl-1,3-propanediamine Chemical compound CNCCCNC UQUPIHHYKUEXQD-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- WTSXICLFTPPDTL-UHFFFAOYSA-N pentane-1,3-diamine Chemical compound CCC(N)CCN WTSXICLFTPPDTL-UHFFFAOYSA-N 0.000 claims 1
- 229940085991 phosphate ion Drugs 0.000 claims 1
- RHPBLLCTOLJFPH-UHFFFAOYSA-N piperidin-2-ylmethanamine Chemical compound NCC1CCCCN1 RHPBLLCTOLJFPH-UHFFFAOYSA-N 0.000 claims 1
- AOHJOMMDDJHIJH-UHFFFAOYSA-N propylenediamine Chemical compound CC(N)CN AOHJOMMDDJHIJH-UHFFFAOYSA-N 0.000 claims 1
- MBYLVOKEDDQJDY-UHFFFAOYSA-N tris(2-aminoethyl)amine Chemical compound NCCN(CCN)CCN MBYLVOKEDDQJDY-UHFFFAOYSA-N 0.000 claims 1
- 210000000689 upper leg Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F226/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
- C08F226/02—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
- C08G73/024—Polyamines containing oxygen in the form of ether bonds in the main chain
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4077—Concentrating samples by other techniques involving separation of suspended solids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4077—Concentrating samples by other techniques involving separation of suspended solids
- G01N2001/4083—Concentrating samples by other techniques involving separation of suspended solids sedimentation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4077—Concentrating samples by other techniques involving separation of suspended solids
- G01N2001/4088—Concentrating samples by other techniques involving separation of suspended solids filtration
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Claims (22)
1. Farmaceutski pripravak koji sadrži umreženi aminski polimer koji veže protone i sadrži ostatak amina koji odgovara Formuli 2:
pri čemu je navedeni umreženi aminski polimer umrežen sa umrežavajućim agensom koji može biti upotrijebljen u reakcijama supstitucijske polimerizacije i reakcijama umrežavanja nakon polimerizacije, gdje je agens za umrežavanje jedan ili više od agensa iz skupine koju čine: dihaloalkan, di(haloalkil)amin, tri(haloalkil)amin, bis(halometil)benzeni, tri(halometil)benzen, tetra(halometil)benzen, 1,2-dibromoetan, 1,3-dikloropropan, 1,2-dikloroetan, 1-bromo-2-kloroetan, 1,3-dibromopropan, bis(2-kloroetil)amin, tris(2-kloroetil)amin, bis(2-kloroetil)metilamin, bis(halometil)benzen, bis(halometil)bifenil, bis(halometil)naftalen, 1,2-bis(3-kloropropilamino)etan, bis(3-kloropropil)amin ili 1,3-dikloropropan i gdje
m i n su nezavisno cijeli brojevi koji nisu negativni;
R10, R20, R30 i R40 su nezavisno vodik, hidrokarbil ili supstituirani hidrokarbil;
X1 je
X2 je hidrokarbil ili supstituirani hidrokarbil;
svaki X11 je nezavisno vodik, hidrokarbil, supstituirani hidrokarbil, hidroksi ili amino; i
z je broj koji nije negativan,
umreženi aminski polimer je sa (i) ravnotežnim kapacitetom vezanja protona od najmanje 5 mmol/g i kapacitetom vezanja kloridnih iona od najmanje 5 mmol/g, u vodenom puferu simulirane želučane tekućine ("SGF") koji sadrži 35 mM NaCl i 63 mM HCl, pri pH 1,2 i na 37°C, (ii) ravnotežnim odnosom bubrenja u deioniziranoj vodi od oko 2 ili manje i (iii) molarnim odnosom vezanja kloridnih iona i fosfatnih iona od najmanje 1:1, tim redom, u vodenom simuliranom anorganskom puferu tankog crijeva ("SIB") koji sadrži 36 mM NaCl, 20 mM NaH2PO4 i 50 mM 2-(N-morfolino)etansulfonske kiseline (MES) i podešen je do pH 5,5, na 37°C.
2. Farmaceutski pripravak prema patentnom zahtjevu 1, gdje je umreženi aminski polimer umrežen s dihaloalkanom.
3. Farmaceutski pripravak prema patentnom zahtjevu 1 ili 2, gdje dihaloalkan sadrži dva ista atoma halogena ili kombinaciju dva različita atoma halogena.
4. Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1-3, gdje je umreženi aminski polimer sa ravnotežnim kapacitetom vezanja klorida od najmanje 7,5 mmol/g u vodenom puferu simulirane želučane tekućine ("SGF") koji sadrži 35 mM NaCl i 63 mM HCl, pH 1,2 i na 37°C.
5. Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1-3, gdje je umreženi aminski polimer sa ravnotežnim kapacitetom vezanja klorida od najmanje 10 mmol/g u vodenom puferu simulirane želučane tekućine ("SGF") koji sadrži 35 mM NaCl i 63 mM HCl, pri pH 1,2 i na 37°C.
6. Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1-5, gdje je X2 alifatičan ili heteroalifatičan.
7. Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1-6, gdje je m 1-3 i X11 je vodik, alifatičan ili heteroalifatičan.
8. Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1-5, gdje umreženi aminski polimer sadrži ostatak amina koji odgovara Formuli 2b:
gdje
m i n su nezavisno cijeli brojevi koji nisu negativni;
svaki R12 je nezavisno vodik, supstituirani hidrokarbil ili hidrokarbil;
R22 i R32 su nezavisno vodik supstituiran hidrokarbil ili hidrokarbil;
R42 je vodik, hidrokarbil ili supstituirani hidrokarbil;
X1 je
X2 je alkil, aminoalkil ili alkanol;
svaki X13 je nezavisno vodik, hidroksi, alicikličan, amino, aminoalkil, halogen, alkil, heteroaril, boronska kiselina ili aril;
z je broj koji nije negativan; i
amin koji odgovara Formuli 2b sadrži najmanje jednu alilnu skupinu.
9. Farmaceutski pripravak prema patentnom zahtjevu 8, gdje su m i z nezavisno 0-3 i n je 0 ili 1.
10. Farmaceutski pripravak prema patentnom zahtjevu 8 ili 9, gdje (i) m je pozitivan cijeli broj i R12, R22 i R42, u kombinaciji, sadrže najmanje dva alilna ili vinilna ostatka ili (ii) n je pozitivan cijeli broj i R12, R32 i R42, u kombinaciji, sadrže najmanje dva alilna ili vinilna ostatka.
11. Farmaceutski pripravak prema patentnom zahtjevu 8 ili 9, gdje je umreženi aminski polimer umrežen sa umrežavajućim agensom izabranim iz skupine koju čine: bis(3-kloropropil)amin, 1,3-dikkloropropan i 1,2-bis(3-kloropropilamino)etan.
12. Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1-5, gdje je umreženi aminski polimer pripremlјen (i) supstitucijskom polimerizacijom polifunkcionalnih reagensa od kojih najmanje jedan sadrži aminske ostatke, (2) radikalskom polimerizacijom monomera koji sadrže najmanje jedan aminski ostatak ili ostatak koji sadrži dušik ili (3) umrežavanjem intermedijera koji sadrži amin s agensom za umrežavanje koji opcionalno sadrži aminske ostatke.
13. Farmaceutski pripravak prema patentnom zahtjevu 12, gdje je umreženi aminski polimer umreženi homopolimer ili umreženi kopolimer.
14. Farmaceutski pripravak prema patentnom zahtjevu 12, gdje je umreženi aminski polimer pripremlјen polimerizacijom monomera koji sadrže amin s agensom za umrežavanje, u reakciji supstitucijske polimerizacije.
15. Farmaceutski pripravak prema patentnom zahtjevu 14, gdje je monomer koji sadrži amin linearni amin koji posjeduje najmanje dva reaktivna aminska ostatka koji sudjeluju u reakciji supstitucijske polimerizacije.
16. Farmaceutski pripravak prema patentnom zahtjevu 14 ili 15, gdje je monomer koji sadrži amin 1,3-bis[bis(2-aminoetil)amino]propan, 3-amino-1-{[2-(bis{2-[bis(3-aminopropil)amino]etil}amino)etil](3-aminopropil)amino}propan, 2-[bis(2-aminoetil)amino]etanamin, tris(3-aminopropil)amin, 1,4-bis[bis(3-aminopropil)amino]butan, 1,2-etandiamin, 2-amino-1-(2-aminoetilamino)etan, 1,2-bis(2-aminoetilamino)etan, 1,3-propandiamin, 3,3'-diaminodipropilamin 2,2-dimetil-1,3-propandiamin, 2-metil-1,3-propandiamin, N,N’-dimetil-1,3-propandiamin, N-metil-1,3-diaminopropan, 3,3’-diamino-N-metildipropilamin, 1,3-diaminopentan, 1,2-diamino-2-metilpropan, 2-metil-1,5-diaminopentan, 1,2-diaminopropan, 1,10-diaminodekan, 1,8-diaminooktan, 1,9-diaminooktan, 1,7-diaminoheptan, 1,6-diaminoheksan, 1,5-diaminopentan, 3-bromopropilamin hidrobromid, N,2-dimetil-1,3-propandiamin, N-izopropil-1,3-diaminopropan, N,N’-bis(2-aminoetil)-1,3-propandiamin, N,N’-bis(3-aminopropil)etilendiamin, N,N’-bis(3-aminopropil)-1,4-butandiamin tetrahidroklorid, 1,3-diamino-2-propanol, N-etiletilendiamin, 2,2'-diamino-N-metildietilamin, N,N’-dietiletilendiamin, N-izopropiletilendiamin, N-metiletilendiamin, N,N’-di-terc-butiletilendiamin, N,N’-diizopropiletilendiamin, N,N’-dimetiletilendiamin, N-butiletilendiamin, 2-(2-aminoetilamino)etanol, 1,4,7,10,13,16-heksaazacikloktadekan, 1,4,7,10-tetraazaciklododekan, 1,4,7-triazaciklononan, N,N’-bis(2-hidroksietil)etilendiamin, piperazin, bis(heksametilen)triamin, N-(3-hidroksipropil)etilendiamin, N-(2-aminoetil)piperazin, 2-metilpiperazin, homopiperazin, 1,4,8,11-tetraazaciklotetradekan, 1,4,8,12-tetraazaciklopentadekan, 2-(aminometil)piperidin ili 3-(metilamino)pirolidino.
17. Farmaceutski pripravak prema patentnom zahtjevu 12, pri čemu priprema umreženog aminskog polimera obuhvaća radikalsku polimerizaciju aminskog monomera koji sadrži najmanje jedan aminski ostatak ili ostatak koji sadrži dušik.
18. Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva, gdje je umreženi aminski polimer sa ravnotežnim odnosom bubrenja u deioniziranoj vodi od oko 1,5 ili manje.
19. Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva, gdje je umreženi aminski polimer sa ravnotežnim odnosom bubrenja u deioniziranoj vodi od oko 1 ili manje.
20. Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva, gdje je umreženi aminski polimer sa molarnim odnosom vezanja kloridnih iona i fosfatnih iona od najmanje 2:1, tim redom, u vodenom simuliranom anorganskom puferu tankog crijeva ("SIB") koji sadrži 36 mM NaCl, 20 mM NaH2PO4 i 50 mM 2-(N-morfolino)etansulfonske kiseline (MES) i podešen je do pH 5,5, na 37°C.
21. Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva, gdje je umreženi aminski polimer sa kapacitetom vezanja protona od najmanje 10 mmol/g i kapacitetom vezanja kloridnih iona od najmanje 10 mmol/g, u vodenom puferu simulirane želučane tekućine ("SGF") koji sadrži 35 mM NaCl i 63 mM HCl, pri pH 1,2 i na 37°C.
22. Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva, za upotrebu u postupku liječenja metaboličke acidoze putem oralne primjene navedene farmaceutske mješavine.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361831445P | 2013-06-05 | 2013-06-05 | |
EP17177221.3A EP3287133B1 (en) | 2013-06-05 | 2014-06-05 | Proton-binding polymers for oral administration |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20191074T1 true HRP20191074T1 (hr) | 2019-09-20 |
Family
ID=51212941
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20171590TT HRP20171590T1 (hr) | 2013-06-05 | 2017-10-18 | Polimeri koji vežu protone za oralnu primjenu |
HRP20191074TT HRP20191074T1 (hr) | 2013-06-05 | 2019-06-14 | Polimeri koji vežu protone za oralnu primjenu |
HRP20201767TT HRP20201767T1 (hr) | 2013-06-05 | 2020-11-02 | Polimeri koji vežu protone za oralnu primjenu |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20171590TT HRP20171590T1 (hr) | 2013-06-05 | 2017-10-18 | Polimeri koji vežu protone za oralnu primjenu |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20201767TT HRP20201767T1 (hr) | 2013-06-05 | 2020-11-02 | Polimeri koji vežu protone za oralnu primjenu |
Country Status (25)
Country | Link |
---|---|
US (8) | US9205107B2 (hr) |
EP (4) | EP3287133B1 (hr) |
JP (4) | JP6453860B2 (hr) |
KR (4) | KR20240023672A (hr) |
CN (3) | CN111671766B (hr) |
AU (3) | AU2014274817B2 (hr) |
BR (1) | BR112015030142B1 (hr) |
CA (1) | CA2912911C (hr) |
CY (3) | CY1119611T1 (hr) |
DK (3) | DK3003327T3 (hr) |
ES (3) | ES2733493T3 (hr) |
HK (3) | HK1222120A1 (hr) |
HR (3) | HRP20171590T1 (hr) |
HU (3) | HUE051198T2 (hr) |
IL (3) | IL242758B (hr) |
LT (3) | LT3287133T (hr) |
MX (3) | MX364785B (hr) |
NO (1) | NO2905572T3 (hr) |
PL (2) | PL3287133T3 (hr) |
PT (3) | PT3003327T (hr) |
RS (2) | RS59033B1 (hr) |
RU (1) | RU2728778C2 (hr) |
SI (3) | SI3578185T1 (hr) |
TR (1) | TR201909355T4 (hr) |
WO (1) | WO2014197725A1 (hr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3287133B1 (en) | 2013-06-05 | 2019-04-17 | Tricida Inc. | Proton-binding polymers for oral administration |
CA3205149A1 (en) * | 2014-12-10 | 2016-06-16 | Tricida, Inc. | Proton-binding polymers for oral administration |
US20190209607A1 (en) | 2016-05-06 | 2019-07-11 | Tricida, Inc. | Compositions for treating acid-base disorders |
AU2017388956A1 (en) | 2016-12-28 | 2019-07-11 | Fujifilm Corporation | Emulsion of nitrogen atom-containing polymer or salt thereof, production method therefor, and production method for particles |
US10934380B1 (en) | 2017-09-25 | 2021-03-02 | Tricida, Inc. | Crosslinked poly(allylamine) polymer pharmaceutical compositions |
EP3698799B1 (en) | 2017-10-16 | 2022-01-26 | FUJIFILM Corporation | Hyperphosphatemia treatment agent |
AU2018360867A1 (en) | 2017-11-03 | 2020-04-30 | Tricida, Inc. | Compositions for and method of treating acid-base disorders |
EP3703707A4 (en) * | 2017-11-03 | 2021-08-11 | Tricida, Inc. | METHOD FOR TREATMENT OF ACID-BASE DISORDER |
CA3102765A1 (en) * | 2018-06-04 | 2019-12-12 | Tricida, Inc. | Method of treating acid-base disorders |
CN114450364A (zh) * | 2019-07-19 | 2022-05-06 | 阿卡特肖勒公司 | 分子上定义明确的抗生物污损和聚离子涂层 |
EP4053179A1 (en) | 2021-03-01 | 2022-09-07 | Tricida Inc. | Crosslinked poly(allylamine) polymer pharmaceutical compositions |
WO2023109825A1 (zh) * | 2021-12-14 | 2023-06-22 | 上海石趣医药科技有限公司 | 氧化银和/或其水合物在制备药物中的用途 |
CN115260355A (zh) * | 2022-05-16 | 2022-11-01 | 江苏中天药业有限公司 | 一种阴离子交换树脂、其制备方法、该树脂与药物的复合物和其掩味制剂 |
KR20230047972A (ko) | 2023-03-21 | 2023-04-10 | 최문수 | 개인별 맞춤형 그립 형상이 형성된 운동기구용 손잡이 |
Family Cites Families (125)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050090553A1 (en) | 1992-06-30 | 2005-04-28 | Shapiro Howard K. | Compositions and method for treatment of chronic inflammatory diseases |
US6444221B1 (en) | 1992-06-30 | 2002-09-03 | Howard K. Shapiro | Methods of treating chronic inflammatory diseases using carbonyl trapping agents |
US5534259A (en) * | 1993-07-08 | 1996-07-09 | Liposome Technology, Inc. | Polymer compound and coated particle composition |
US5496545A (en) | 1993-08-11 | 1996-03-05 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
US5667775A (en) | 1993-08-11 | 1997-09-16 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
US5648355A (en) | 1994-02-09 | 1997-07-15 | Kos Pharmaceutical, Inc. | Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin |
TW474813B (en) | 1994-06-10 | 2002-02-01 | Geltex Pharma Inc | Alkylated composition for removing bile salts from a patient |
AU703842B2 (en) | 1994-10-17 | 1999-04-01 | Robert M. Bersin | Compositions comprising carbonate/bicarbonate buffered dichloroacetic acid and methods for treatment of metabolic and cardiovascular disorders |
US20020006899A1 (en) | 1998-10-06 | 2002-01-17 | Pospisilik Andrew J. | Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals |
US5753706A (en) | 1996-12-16 | 1998-05-19 | Hsu; Chen Hsing | Methods for treating renal failure |
AUPO758297A0 (en) | 1997-06-27 | 1997-07-24 | Rowe, James Baber | Control of acidic gut syndrome |
US6726905B1 (en) | 1997-11-05 | 2004-04-27 | Genzyme Corporation | Poly (diallylamines)-based phosphate binders |
JP2002500201A (ja) * | 1998-01-05 | 2002-01-08 | ユニバーシティ オブ ワシントン | 膜破壊剤を使用する増強された輸送 |
WO1999040990A1 (en) | 1998-02-17 | 1999-08-19 | University Of Maryland | Anion binding polymers and the use thereof |
US6485703B1 (en) | 1998-07-31 | 2002-11-26 | The Texas A&M University System | Compositions and methods for analyte detection |
US6271264B1 (en) | 1998-12-01 | 2001-08-07 | Geltex Pharmaceuticals, Inc. | Polymers containing spirobicyclic ammonium moieties as bile acid sequestrants |
US6733780B1 (en) | 1999-10-19 | 2004-05-11 | Genzyme Corporation | Direct compression polymer tablet core |
GB9927088D0 (en) | 1999-11-17 | 2000-01-12 | Secr Defence | Use of poly(diallylamine) polymers |
WO2001066606A1 (fr) | 2000-03-09 | 2001-09-13 | Hisamitsu Pharmaceutical Co., Inc. | Resine echangeuse d'anions reticulee ou sel de celle-ci |
US6844372B2 (en) | 2000-03-09 | 2005-01-18 | Hisamitsu Pharmaceutical Co., Inc. | Crosslinked anion-exchange resin or salt thereof and phosphorus adsorbent comprising the same |
WO2001068106A1 (fr) | 2000-03-13 | 2001-09-20 | Hisamitsu Pharmaceutical Co., Inc. | Prophylactiques et/ou remedes pour hyperphosphatemie |
JP2002028737A (ja) | 2000-07-07 | 2002-01-29 | Fujitsu Ltd | プレス打ち抜き加工方法及びプレス打ち抜き加工装置 |
CA2444347A1 (en) | 2001-04-18 | 2002-10-31 | Genzyme Corporation | Method for treating gout and binding uric acid |
CA2444587C (en) * | 2001-04-18 | 2008-10-21 | Genzyme Corporation | Pharmaceutical compositions of low salt polyallylamine hydrochloride |
US20050234129A1 (en) | 2002-03-11 | 2005-10-20 | Sutton Paul A | Salts of nateglinide |
CA2514071A1 (en) | 2003-02-10 | 2004-08-19 | Autogen Research Pty Ltd | Therapeutic molecules |
TWI335218B (en) | 2003-02-19 | 2011-01-01 | Panion & Bf Biotech Inc | Ferric organic compounds, uses thereof and methods of making same |
CN1540136A (zh) * | 2003-10-27 | 2004-10-27 | 华东理工大学 | 一种评价微生物驱油能力的方法 |
US7608674B2 (en) * | 2003-11-03 | 2009-10-27 | Ilypsa, Inc. | Pharmaceutical compositions comprising cross-linked small molecule amine polymers |
US7449605B2 (en) | 2003-11-03 | 2008-11-11 | Ilypsa, Inc. | Crosslinked amine polymers |
US7385012B2 (en) | 2003-11-03 | 2008-06-10 | Ilypsa, Inc. | Polyamine polymers |
US7767768B2 (en) | 2003-11-03 | 2010-08-03 | Ilypsa, Inc. | Crosslinked amine polymers |
US7459502B2 (en) | 2003-11-03 | 2008-12-02 | Ilypsa, Inc. | Pharmaceutical compositions comprising crosslinked polyamine polymers |
US7335795B2 (en) | 2004-03-22 | 2008-02-26 | Ilypsa, Inc. | Crosslinked amine polymers |
CA2551528A1 (en) | 2003-12-31 | 2005-07-21 | Genzyme Corporation | Enteric coated aliphatic amine polymer bile acid sequestrants |
WO2005072773A1 (ja) | 2004-01-29 | 2005-08-11 | Keio University | 赤血球機能修飾物質 |
EP1732523B9 (en) | 2004-03-30 | 2010-06-02 | Relypsa, Inc. | Potassium binding polymers and uses thereof |
US8192758B2 (en) | 2004-03-30 | 2012-06-05 | Relypsa, Inc. | Ion binding compositions |
US7556799B2 (en) | 2004-03-30 | 2009-07-07 | Relypsa, Inc. | Ion binding polymers and uses thereof |
US8282960B2 (en) | 2004-03-30 | 2012-10-09 | Relypsa, Inc. | Ion binding compositions |
US7429394B2 (en) | 2004-03-30 | 2008-09-30 | Relypsa, Inc. | Ion binding compositions |
US7854924B2 (en) | 2004-03-30 | 2010-12-21 | Relypsa, Inc. | Methods and compositions for treatment of ion imbalances |
US8399025B2 (en) | 2004-06-04 | 2013-03-19 | Board Of Regents, The University Of Texas System | Polyamine modified particles |
PL1771192T3 (pl) | 2004-07-19 | 2019-02-28 | N.V. Nutricia | Stosowanie asparaginianu do regulowania poziomów glukozy we krwi |
DE102004035808A1 (de) | 2004-07-21 | 2006-03-16 | Kasch, Helmut, Dr. | Ammoniumsalze und Ammoniumsalz-Mineralsalzchlatrate als Transport- und Wirkform für pharmazeutische-medizinische und als Phasentransfermittel für chemische Anwendungen |
US8569277B2 (en) | 2004-08-11 | 2013-10-29 | Palo Alto Investors | Methods of treating a subject for a condition |
US20080214440A1 (en) | 2004-10-08 | 2008-09-04 | Forbes Medi-Tech (Research), Inc. | Vasoactive intestinal polypeptide compositions |
US20070293429A1 (en) | 2004-10-08 | 2007-12-20 | Therapei Pharmaceuticals, Inc. | Vasoactive Intestinal Polypeptide Compositions |
JP2008531751A (ja) * | 2004-10-13 | 2008-08-14 | イリプサ, インコーポレイテッド | 架橋アミンポリマー |
US7985418B2 (en) | 2004-11-01 | 2011-07-26 | Genzyme Corporation | Aliphatic amine polymer salts for tableting |
ITME20040015A1 (it) | 2004-12-07 | 2005-03-07 | Vincenzo Savica | Chewing gum, caramelle gommose, pastiglie, compresse a lento rilascio di chelanti fosfato e/o fosforo salivare e capsule a lento rilascio di chelanti fosfato e/o fosforo a livello gastroenterico. |
WO2006078629A2 (en) * | 2005-01-18 | 2006-07-27 | Duke University | In-situ crosslinkable elastin-like polypeptides for defect filling in cartilaginous tissue repair |
US20080200533A1 (en) | 2005-07-04 | 2008-08-21 | Ramu Krishnan | Drug or Pharmaceutical Compounds and a Preparation Thereof |
MX2008002360A (es) | 2005-08-18 | 2008-04-29 | Globoasia Llc | Compuestos organicos ferricos grado farmaceutico, uso de los mismos y metodos para elaborar los mismos. |
CA2620406A1 (en) | 2005-09-02 | 2007-03-08 | Genzyme Corporation | Method for removing phosphate and polymer used therefore |
DE112006002617T5 (de) | 2005-09-30 | 2008-08-28 | Ilypsa Inc., Santa Clara | Verfahren zur Herstellung von Core-Shell-Kompositen bzw. Kern-Hüllen-Kompositen mit vernetzten Hüllen und daraus entstehende Core-Shell-Komposite |
GB2446077B (en) * | 2005-09-30 | 2010-10-13 | Ilypsa Inc | Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal |
WO2007038801A2 (en) | 2005-09-30 | 2007-04-05 | Ilypsa, Inc. | Monovalent cation-binding compositions comprising core-shell particles having crosslinked poly-vinylic shells, and methods of use thereof |
EP1946763B1 (en) | 2005-11-08 | 2013-08-21 | Ajinomoto Co., Inc. | Promoter for recovery from anesthesia |
WO2007056405A2 (en) | 2005-11-08 | 2007-05-18 | Genzyme Corporation | Magnesium-containing polymers for the treatment of hyperphosphatemia |
ITMI20052461A1 (it) | 2005-12-22 | 2007-06-23 | Univ Degli Studi Milano | Sistemi microparticellari per la somministrazione orale di sostanze biologicamente attive |
RU2008136081A (ru) | 2006-02-14 | 2010-03-20 | Тева Фармасьютикл Индастриес Лтд. (Il) | Фармацевтические составы с алифатическими аминными полимерами и способы их производства |
WO2007130463A2 (en) | 2006-05-05 | 2007-11-15 | Genzyme Corporation | Amine condensation polymers as phosphate sequestrants |
EP2043627A2 (en) | 2006-07-05 | 2009-04-08 | Genzyme Corporation | Iron(ii)-containing treatments for hyperphosphatemia |
CA2658338A1 (en) | 2006-07-18 | 2008-01-24 | Genzyme Corporation | Amine dendrimers |
CN101541235A (zh) * | 2006-07-18 | 2009-09-23 | 基酶有限公司 | 胺类树状物 |
US8391873B2 (en) | 2006-07-21 | 2013-03-05 | Qualcomm Incorporated | Systems and methods for coordinating supplementary services for voice telephone calls in a centralized fashion |
EP2046284A1 (en) | 2006-08-04 | 2009-04-15 | Nastech Pharmaceutical Company Inc. | Compositions for intranasal delivery of human insulin and uses thereof |
US8187634B2 (en) | 2006-09-01 | 2012-05-29 | Usv, Ltd. | Process for the preparation of sevelamer hydrochloride and formulation thereof |
JP2010504285A (ja) | 2006-09-01 | 2010-02-12 | ゲンズイメ コーポレーション | デンドリマー組成物 |
US7964182B2 (en) * | 2006-09-01 | 2011-06-21 | USV, Ltd | Pharmaceutical compositions comprising phosphate-binding polymer |
JP5427029B2 (ja) | 2006-09-06 | 2014-02-26 | スキャンポ・アーゲー | 消化管の重炭酸分泌を促進するための方法および組成物 |
BRPI0717545A2 (pt) | 2006-09-29 | 2013-10-22 | Gezyme Corp | Composição farmacêutica, método para tratar uma doença, polímero de amida, rede de polímero, e, método para preparar um polímero de amida |
EP2120972A1 (en) | 2006-12-14 | 2009-11-25 | Genzyme Corporation | Amido-amine polymer compositions |
US20100129309A1 (en) | 2007-02-23 | 2010-05-27 | Dhal Pradeep K | Amine polymer compositions |
US20080207766A1 (en) | 2007-02-27 | 2008-08-28 | Agi Therapeutics Research Ltd. | Methods and compositions for treating at least one upper gastrointestinal symptom |
EP2131820A1 (en) | 2007-03-08 | 2009-12-16 | Genzyme Corporation | Sulfone polymer compositions |
TWI445540B (zh) | 2007-04-20 | 2014-07-21 | Ajinomoto Kk | 抗低體溫組成物 |
WO2008133954A1 (en) | 2007-04-27 | 2008-11-06 | Genzyme Corporation | Amido-amine dendrimer compositions |
WO2009005838A2 (en) | 2007-07-02 | 2009-01-08 | Cognate3 Llc | Process for the preparation of a non-corrosive base solution and methods of using same |
CN101687961B (zh) * | 2007-07-11 | 2011-10-05 | 东丽株式会社 | 交联聚烯丙胺或其酸加成盐及其医药用途 |
EP2016947A1 (en) | 2007-07-17 | 2009-01-21 | Chemo Ibérica, S.A. | Novel one step process for preparing cross-linked poly(allylamine) polymers |
WO2009023544A2 (en) | 2007-08-10 | 2009-02-19 | Ilypsa, Inc. | Dosage unit anion-exchange polymer pharmaceutical compositions |
US20090181359A1 (en) * | 2007-10-25 | 2009-07-16 | Lou Sheng C | Method of performing ultra-sensitive immunoassays |
US20090156647A1 (en) | 2007-12-12 | 2009-06-18 | Iovate T. & P. Inc. | Method for maintaining physiological pH levels during intensive physical exercise |
JP2011506449A (ja) | 2007-12-14 | 2011-03-03 | ジェンザイム コーポレーション | コーティング医薬組成物 |
PA8807201A1 (es) | 2007-12-14 | 2009-07-23 | Genzyme Corp | Composiciones farmaceuticas |
WO2009097127A1 (en) | 2008-01-31 | 2009-08-06 | Genzyme Corporation | Pharmaceutical compositions |
EA201071059A1 (ru) | 2008-03-11 | 2011-04-29 | Лайвайонекс Инк. | Способы и композиции для лечения воспаления и связанных с воспалением патологических состояний |
CA2720865A1 (en) | 2008-04-08 | 2009-10-15 | Usv Limited | Process for preparation of amine polymer salt |
ES2380162T3 (es) | 2008-04-11 | 2012-05-09 | Gp Investimenti S.R.L. | Dispositivo de uso manual para el tratamiento de tejido humano con ultrasonidos |
US20110142952A1 (en) | 2008-06-20 | 2011-06-16 | Harris David J | Pharmaceutical Compositions |
DE102008030046A1 (de) | 2008-06-25 | 2009-12-31 | Ratiopharm Gmbh | Kompaktiertes Polyallylamin-Polymer |
US20100008988A1 (en) | 2008-07-14 | 2010-01-14 | Glenmark Generics, Ltd. | Tablet compositions of amine polymers |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
WO2010022381A1 (en) | 2008-08-22 | 2010-02-25 | Relypsa, Inc. | Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties |
US8337824B2 (en) | 2008-08-22 | 2012-12-25 | Relypsa, Inc. | Linear polyol stabilized polyfluoroacrylate compositions |
MX342439B (es) | 2008-09-25 | 2016-09-29 | Vive Nano Inc * | Metodos para producir nanoparticulas polimericas y formulaciones de ingredientes activos. |
US20110268666A1 (en) | 2008-09-29 | 2011-11-03 | Yissum Research Development Company of the Research University of Jerusalem, Ltd. | Novel gastroretentive delivery system |
WO2010059384A1 (en) | 2008-10-30 | 2010-05-27 | Janssen Pharmaceutica Nv | Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives useful as gdir agonists |
US20100166861A1 (en) | 2008-12-29 | 2010-07-01 | Kelly Noel Lynch | Pharmaceutical formulations of sevalamer, or salts thereof, and copovidone |
BRPI1006969A2 (pt) | 2009-01-22 | 2016-04-12 | Usv Ltd | composições farmacêuticas compreendendo polímero de ligação a fosfato |
EP2488172A4 (en) | 2009-10-13 | 2014-08-13 | Univ Michigan | DENDRIMER COMPOSITION AND METHOD FOR THEIR SYNTHESIS |
EA024699B1 (ru) | 2009-10-22 | 2016-10-31 | Синтон Б. В. | Фармацевтическая таблетка с немедленным высвобождением, содержащая севеламера карбонат |
EP2509992B1 (en) | 2009-12-07 | 2015-10-14 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
BR112012021446A2 (pt) * | 2010-02-24 | 2016-05-31 | Relypsa Inc | polímero de amina, composição farmacêutica, método de redução do colesterol ldl sérico em um indivíduo, método para tratar doença, métodos de remoção de sais biliares de um indivíduo animal, e para melhorar o controle glicêmico em um indivíduo, e, processo para preparar o polímero de amina. |
EP2539380B1 (en) | 2010-02-24 | 2015-08-19 | Relypsa, Inc. | Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants |
EP3130343B1 (en) * | 2010-02-24 | 2018-05-09 | Relypsa, Inc. | Polyimidazoles for use as bile acid sequestrants |
RU2417782C1 (ru) * | 2010-03-03 | 2011-05-10 | Федеральное государственное образовательное учреждение высшего профессионального образования "Белгородская государственная сельскохозяйственная академия" | Способ лечения ацидоза рубца |
IT1406068B1 (it) | 2010-07-22 | 2014-02-06 | Medestea Int Spa | Polidesossiribonucleotidi (pdrn) per l'impiego nel trattamento di condizioni di acidosi e composizioni a base di polidesossiribonucleotidi per il suddetto impiego |
SG187787A1 (en) * | 2010-08-10 | 2013-03-28 | Amgen Inc | Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies |
US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
KR101238210B1 (ko) | 2011-06-30 | 2013-03-04 | 엘지전자 주식회사 | 이동 단말기 |
US20130137772A1 (en) | 2011-11-29 | 2013-05-30 | Raymond J. Bergeron | Hydroxypolyamine salts |
EA201590062A1 (ru) | 2012-06-21 | 2016-02-29 | Керикс Байофармасьютикалз, Инк. | Применение лимонно-кислого железа при лечении пациентов с хронической почечной недостаточностью |
KR20210005314A (ko) | 2012-10-08 | 2021-01-13 | 리립사, 인크. | 고혈압 및 고칼륨혈증을 치료하기 위한 칼륨-결합제 |
EP3287133B1 (en) * | 2013-06-05 | 2019-04-17 | Tricida Inc. | Proton-binding polymers for oral administration |
AU2014341975A1 (en) | 2013-11-04 | 2016-05-19 | Keryx Biopharmaceuticals, Inc. | Ferric citrate for reducing cardiac failure in chronic kidney disease patients |
CA3205149A1 (en) | 2014-12-10 | 2016-06-16 | Tricida, Inc. | Proton-binding polymers for oral administration |
US20190209607A1 (en) | 2016-05-06 | 2019-07-11 | Tricida, Inc. | Compositions for treating acid-base disorders |
EP3703707A4 (en) | 2017-11-03 | 2021-08-11 | Tricida, Inc. | METHOD FOR TREATMENT OF ACID-BASE DISORDER |
AU2018360867A1 (en) | 2017-11-03 | 2020-04-30 | Tricida, Inc. | Compositions for and method of treating acid-base disorders |
WO2019236124A1 (en) | 2018-06-04 | 2019-12-12 | Tricida, Inc. | Method of treating acid-base disorders |
WO2019236639A1 (en) | 2018-06-04 | 2019-12-12 | Tricida, Inc. | Method of treating acid-base disorders |
CA3102765A1 (en) | 2018-06-04 | 2019-12-12 | Tricida, Inc. | Method of treating acid-base disorders |
-
2014
- 2014-06-05 EP EP17177221.3A patent/EP3287133B1/en active Active
- 2014-06-05 DK DK14742001.2T patent/DK3003327T3/en active
- 2014-06-05 SI SI201431698T patent/SI3578185T1/sl unknown
- 2014-06-05 SI SI201430466T patent/SI3003327T1/en unknown
- 2014-06-05 PT PT147420012T patent/PT3003327T/pt unknown
- 2014-06-05 KR KR1020247003745A patent/KR20240023672A/ko active Search and Examination
- 2014-06-05 MX MX2015016527A patent/MX364785B/es active IP Right Grant
- 2014-06-05 CA CA2912911A patent/CA2912911C/en active Active
- 2014-06-05 JP JP2016518006A patent/JP6453860B2/ja active Active
- 2014-06-05 PT PT191692599T patent/PT3578185T/pt unknown
- 2014-06-05 PL PL17177221T patent/PL3287133T3/pl unknown
- 2014-06-05 TR TR2019/09355T patent/TR201909355T4/tr unknown
- 2014-06-05 HU HUE19169259A patent/HUE051198T2/hu unknown
- 2014-06-05 RU RU2015155596A patent/RU2728778C2/ru active
- 2014-06-05 LT LTEP17177221.3T patent/LT3287133T/lt unknown
- 2014-06-05 BR BR112015030142-8A patent/BR112015030142B1/pt active IP Right Grant
- 2014-06-05 KR KR1020237024806A patent/KR102633597B1/ko active IP Right Grant
- 2014-06-05 HU HUE14742001A patent/HUE034836T2/en unknown
- 2014-06-05 LT LTEP19169259.9T patent/LT3578185T/lt unknown
- 2014-06-05 PL PL14742001T patent/PL3003327T3/pl unknown
- 2014-06-05 RS RS20190806A patent/RS59033B1/sr unknown
- 2014-06-05 DK DK17177221.3T patent/DK3287133T3/da active
- 2014-06-05 EP EP20183421.5A patent/EP3812761A1/en active Pending
- 2014-06-05 CN CN202010780603.3A patent/CN111671766B/zh active Active
- 2014-06-05 ES ES17177221T patent/ES2733493T3/es active Active
- 2014-06-05 CN CN201480032395.1A patent/CN105377270B/zh active Active
- 2014-06-05 EP EP14742001.2A patent/EP3003327B1/en active Active
- 2014-06-05 CN CN202010780604.8A patent/CN111671767B/zh active Active
- 2014-06-05 KR KR1020217034420A patent/KR20210131457A/ko not_active Application Discontinuation
- 2014-06-05 PT PT17177221T patent/PT3287133T/pt unknown
- 2014-06-05 EP EP19169259.9A patent/EP3578185B1/en active Active
- 2014-06-05 HU HUE17177221A patent/HUE043999T2/hu unknown
- 2014-06-05 AU AU2014274817A patent/AU2014274817B2/en active Active
- 2014-06-05 WO PCT/US2014/041152 patent/WO2014197725A1/en active Application Filing
- 2014-06-05 DK DK19169259.9T patent/DK3578185T3/da active
- 2014-06-05 RS RS20201307A patent/RS61005B1/sr unknown
- 2014-06-05 ES ES14742001.2T patent/ES2646271T3/es active Active
- 2014-06-05 SI SI201431241T patent/SI3287133T1/sl unknown
- 2014-06-05 KR KR1020157036999A patent/KR102318910B1/ko active IP Right Grant
- 2014-06-05 LT LTEP14742001.2T patent/LT3003327T/lt unknown
- 2014-06-05 ES ES19169259T patent/ES2834485T3/es active Active
- 2014-06-23 US US14/311,852 patent/US9205107B2/en active Active
-
2015
- 2015-01-27 NO NO15000230A patent/NO2905572T3/no unknown
- 2015-11-18 US US14/944,844 patent/US9925214B2/en active Active
- 2015-11-24 IL IL242758A patent/IL242758B/en active IP Right Grant
- 2015-12-01 MX MX2019005300A patent/MX2019005300A/es unknown
- 2015-12-01 MX MX2021013880A patent/MX2021013880A/es unknown
-
2016
- 2016-08-30 HK HK16110308.8A patent/HK1222120A1/zh unknown
- 2016-10-05 HK HK16111588.7A patent/HK1223288A1/zh unknown
-
2017
- 2017-09-26 US US15/715,934 patent/US9993500B2/en active Active
- 2017-10-18 HR HRP20171590TT patent/HRP20171590T1/hr unknown
- 2017-11-06 CY CY20171101159T patent/CY1119611T1/el unknown
-
2018
- 2018-06-07 US US16/002,306 patent/US10391118B2/en active Active
- 2018-06-07 US US16/002,269 patent/US10363268B2/en active Active
- 2018-08-16 HK HK18110550.1A patent/HK1251151B/zh unknown
- 2018-12-13 JP JP2018233254A patent/JP6759316B2/ja active Active
-
2019
- 2019-04-04 US US16/375,843 patent/US10369169B1/en active Active
- 2019-06-14 HR HRP20191074TT patent/HRP20191074T1/hr unknown
- 2019-07-04 CY CY20191100694T patent/CY1121801T1/el unknown
- 2019-08-16 US US16/542,969 patent/US11197887B2/en active Active
- 2019-08-22 AU AU2019219800A patent/AU2019219800B1/en active Active
- 2019-12-04 AU AU2019275584A patent/AU2019275584B2/en active Active
-
2020
- 2020-01-09 IL IL271932A patent/IL271932B/en active IP Right Grant
- 2020-09-02 JP JP2020147224A patent/JP7075455B2/ja active Active
- 2020-10-20 IL IL278183A patent/IL278183B/en unknown
- 2020-10-30 CY CY20201101028T patent/CY1123673T1/el unknown
- 2020-11-02 HR HRP20201767TT patent/HRP20201767T1/hr unknown
-
2021
- 2021-12-09 US US17/546,339 patent/US20220096534A1/en active Pending
-
2022
- 2022-05-13 JP JP2022079329A patent/JP2022107004A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20191074T1 (hr) | Polimeri koji vežu protone za oralnu primjenu | |
JP2016520652A5 (hr) | ||
ATE424437T1 (de) | Biozide beschichtungen | |
JP2017516884A5 (hr) | ||
JP2004526778A5 (hr) | ||
JP2012522818A5 (hr) | ||
JP2016508144A5 (hr) | ||
JP2013057058A5 (ja) | ブロック共重合体の塗膜 | |
JP2004500459A5 (hr) | ||
HRP20200689T1 (hr) | Polimeri koji vežu protone za oralnu primjenu | |
JP2014515406A5 (hr) | ||
BR112020002147A2 (pt) | composição e método para melhorar a estabilidade de composições de espuma aquosas e resistentes ao álcool | |
JP2014528836A5 (hr) | ||
CA2620406A1 (en) | Method for removing phosphate and polymer used therefore | |
RU2012142239A (ru) | Полимеры для очистки от металлов | |
JPWO2015045883A1 (ja) | (メタ)アクリル酸系共重合体とその製造方法 | |
JP2009143975A (ja) | 固体電解質用材料 | |
MX265090B (es) | Copolimeros y su empleo en composiciones para el cuidado personal. | |
CN106719681B (zh) | 一种油田杀菌缓蚀剂及其制备方法 | |
Taden et al. | Synthesis and polymerization of 5‐(methacrylamido) tetrazole, a water‐soluble acidic monomer | |
Korpe et al. | Crosslinked DADMAC polymers as cationic super absorbents | |
GB1302167A (hr) | ||
JP2020069414A (ja) | 二酸化炭素の分離組成物 | |
JP2007335119A (ja) | 固体電解質用材料 | |
ES422718A1 (es) | Procedimiento para la preparacion de una resina polimerica reticulada. |